Innovative Horizons: Perfusion-driven Process Intensification for HEK293 cells in Cell and Gene Therapy

The rapid advancement of cell and gene therapies opened new avenues for treating diseases once considered incurable. Despite this progress, high cost and limited availability of these therapies present significant challenges, necessitating solutions to meet the growing demand from eligible patients. While perfusion-based process intensification techniques have been the standard in protein-based therapies produced in CHO cells for years, they remain a novel and expanding field for HEK293 cells. The use of HEK293 cells offers the advantage of producing not only proteins but also various viral vectors, such as Adeno-Associated Virus (AAV), Lentivirus (LV) and Adenovirus (AdV).